P. Siegl

发表

Current Practices in Safety Pharmacology

Dennis Murphy, Gary A. Gintant, Roger D. Porsolt, 2010 .

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

R. Young, J. Mancini, M. Turner, 2003, Journal of medicinal chemistry.

A novel multiple-stage antimalarial agent that inhibits protein synthesis

David W. Gray, E. Winzeler, S. Meister, 2015, Nature.

Safety pharmacology in 2010 and beyond: survey of significant events of the past 10 years and a roadmap to the immediate-, intermediate- and long-term future in recognition of the tenth anniversary of the Safety Pharmacology Society.

J. Valentin, A. Bass, L. Kinter, 2011, Journal of pharmacological and toxicological methods.

Angiotensin II receptor antagonists containing a phenylpyridine element

R. Chang, P. Siegl, N. Mantlo, 1993 .

Cardiovascular and Renal Review: Pharmacology of Angiotensin II Receptor Antagonists: Comparison with Renin Inhibitors and Angiotensin-Converting Enzyme Inhibitors

T. Broten, P. Siegl, S. Kivlighn, 1994 .

In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist.

W. Greenlee, R. Chang, A. Patchett, 1992, The Journal of pharmacology and experimental therapeutics.

In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.

W. Greenlee, R. Chang, A. Patchett, 1992, The Journal of pharmacology and experimental therapeutics.

Endothelin-B Receptors in Cerebral Resistance Arterioles and their Functional Significance after Focal Cerebral Ischemia in Cats

J. Mcculloch, O. Touzani, P. Siegl, 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

A. Bass, L. Kinter, P. Siegl, 2004, Journal of pharmacological and toxicological methods.

Safety Pharmacology: Guidelines S7A and S7B

J. Koerner, P. Siegl, 2013 .

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria

B. Darpo, B. Laurijssens, S. Toovey, 2015, British journal of clinical pharmacology.

Use of Radionuclides in Experimental Vascular Thrombosis

P. Siegl, L. Schaffer, J. T. Davidson, 1993 .

Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts.

M. Sanguinetti, P. Siegl, C. Wolleben, 1989, Journal of molecular and cellular cardiology.

L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro

W. Schleif, J. Quintero, E. Emini, 1992, Antimicrobial Agents and Chemotherapy.

BRL 34915 (cromakalim) activates ATP-sensitive K+ current in cardiac muscle.

M. Sanguinetti, P. Siegl, A. Scott, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

S. Prahalada, Y. Shen, J. Lynch, 1998, The American journal of physiology.

Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure.

S. Prahalada, You-tang Shen, J. Lynch, 1998, American journal of physiology. Heart and circulatory physiology.

Positive cooperativity of ryanodine binding to the calcium release channel of sarcoplasmic reticulum from heart and skeletal muscle.

S. Fleischer, S. McGrew, M. Inui, 1989, Biochemistry.

Ventricular Atrial Natriuretic Factor in the Cardiomyopathic Hamster Model of Congestive Heart Failure

R. Dixon, H. Franch, P. Siegl, 1988, Circulation research.

In vitro pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors.

W. Greenlee, R. Chang, P. Kling, 1995, European journal of pharmacology.

Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa.

C. Dunwiddie, P. Siegl, A. B. Lenny, 1991, Archives of biochemistry and biophysics.

Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.

T. Hayama, J. O'brien, S. Ozaki, 1999, The Journal of pharmacology and experimental therapeutics.

Responses to Amrinone in Isolated Cardiac Muscles from Cat, Rabbit, and Guinea Pig

C. Sweet, P. Siegl, G. Morgan, 1984, Journal of cardiovascular pharmacology.

[A method of early diagnostic monitoring in manganese exposure].

P. Siegl, K. Bergert, 1982, Zeitschrift fur die gesamte Hygiene und ihre Grenzgebiete.

Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa.

M. Sardana, M. Neeper, R. Ellis, 1990, The Journal of biological chemistry.

A rapid bioassay for the determination of non-nucleoside HIV-1 reverse transcriptase inhibitor plasma levels.

S. Smith, M. Goldman, J. O'brien, 1993, Life sciences.

Leukotriene D4 increases both the force of contraction and polyphosphoinositide formation in guinea-pig papillary muscle.

P. Siegl, D. Aharony, A. Scott, 1991, European journal of pharmacology.

Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954.

T. Miyauchi, H. Ohta, P. Siegl, 2000, Journal of cardiovascular pharmacology.

Chronotropic stimulation: a primary effector for release of atrial natriuretic factor.

P. A. Friedman, P. Siegl, G. Bilder, 1989, Circulation research.

Regional vasorelaxant selectivity of atrial natriuretic factor in isolated rabbit vessels.

E. Faison, P. Siegl, G. Morgan, 1985, Life sciences.

Cardiac angiotensin receptors: effects of selective angiotensin II receptor antagonists, DUP 753 and PD 121981, in rabbit heart.

R. Chang, P. Siegl, V. Lotti, 1992, The Journal of pharmacology and experimental therapeutics.

Monthly Updates—Cardiovascular & Renal: Epidemiology and Cardiovascular Drug Discovery Through the 1990s

M. Goldberg, P. Siegl, 1995 .

Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist.

P. Siegl, 1993, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons.

C. Dunwiddie, P. Siegl, G. Vlasuk, 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

Mechanism of Action

M. Sanguinetti, N. Jurkiewicz, P. Siegl, 2005 .

Drugs for prevention of malignant ventricular arrhythmias

J. Lynch, P. Siegl, 1994 .

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.

J J Baldwin, M. Sanguinetti, R. Freidinger, 1997, Journal of medicinal chemistry.

Cardiovascular controversies Blockers of ATP sensitive potassium current are of potential benefit in ischaemic heart disease

P. Siegl, 2007 .

Angiotensin II receptor subtypes in renal cortex of rats and rhesus monkeys.

J. D. Frank, R. Gibson, P. Siegl, 1991, The American journal of physiology.

Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes. Mechanism of action.

M. Sanguinetti, N. Jurkiewicz, P. Siegl, 1991, Circulation research.

The negative inotropic potency of compound D 600 in rat, guinea pig, and rabbit cardiac preparations.

J. McNeill, P. Siegl, 1980, Canadian journal of physiology and pharmacology.

Interactions of DPI 201-106, a novel cardiotonic agent, with cardiac calcium channels

G. Kaczorowski, P. Siegl, G. Morgan, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

L‐368,899, a potent orally active oxytocin antagonist for potential use in preterm labor

B. E. Evans, M. Kaufman, D. Veber, 1993 .

Pathophysiological roles of endothelin-1 in Dahl salt-sensitive hypertension.

T. Miyauchi, S. Maeda, H. Ohta, 1999, Hypertension.

Endothelin as a target for drug development: Recent progress

P. Siegl, 1994 .

Chapter 7. Angiotensin / Renin Modulators

W. Greenlee, P. Siegl, 1991 .

Actions of mescaline on isolated rat atria.

P. Siegl, R. Orzechowski, 1977, Journal of pharmaceutical sciences.

Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.

B. Francis, R. Gibson, P. Siegl, 1993, Thrombosis research.

Recombinant leech antiplatelet protein prevents collagen-mediated platelet aggregation but not collagen graft thrombosis in baboons.

R. Nutt, S. Brady, R. Gould, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Effects of a specific bradycardic agent (AQ-A39) and verapamil on beta-adrenergic responses in isolated guinea pig atria.

P. Siegl, G. Morgan, 1987, Canadian journal of physiology and pharmacology.

Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide: A Potent Inhibitor of Coagulation Factor Xa in a Primate Model of Arterial Thrombosis

P. Siegl, G. Vlasuk, L. Schaffer, 1991, Circulation.

Synthesis of new imidazo[1,2-b]pyridazine isosteres of potent imidazo[4,5-b]pyridine angiotensin II antagonists

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles.

W. Greenlee, R. Chang, V. J. Lotti, 1993, Journal of medicinal chemistry.

(Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.

R. Chang, V. J. Lotti, A. Patchett, 1993, Journal of medicinal chemistry.

Non-peptide angiotensin II receptor antagonists. 2. Design, synthesis, and biological activity of N-substituted (phenylamino)phenylacetic acids and acyl sulfonamides.

W. Greenlee, R. Chang, V. J. Lotti, 1993, Journal of medicinal chemistry.

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists.

R. Chang, V. J. Lotti, P. Chakravarty, 1991, Journal of medicinal chemistry.

Renin inhibitors containing C-termini derived from mercaptoheterocycles.

W. Greenlee, A. Patchett, R. Tolman, 1992, Journal of medicinal chemistry.

The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptors

W. Greenlee, R. Chang, V. J. Lotti, 1995 .

Chapter 7. Anglotensln / Renln Modulators

W. Greenlee, P. Siegl, 1992 .

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum

Sandhya Kortagere, Thomas D. Otto, Vicky M. Avery, 2014, Nature Communications.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria

R. Price, K. Chibale, Dale Taylor, 2018, Antimicrobial Agents and Chemotherapy.

Negative lusitropic effect of DPI 201-106 and E4031. Possible role of prolonging action potential duration.

H. Cingolani, J. Lynch, P. Siegl, 1990, Journal of molecular and cellular cardiology.

The cholecystokinin receptor antagonist devazepide enhances morphine-induced analgesia but not morphine-induced respiratory depression in the squirrel monkey.

S. Iversen, C. Dourish, P. Siegl, 1990, The Journal of pharmacology and experimental therapeutics.

Relevance of a standard food model in combination with electronic jaw movement recording on human mastication pattern analysis

P. Siegl, G. Slavicek, H. Gruber, 2010 .

A novel standard food model to analyze the individual parameters of human mastication

G. Slavicek, P. Siegl, Mikhael Soykher, 2009 .

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

David M. Shackleford, R. Price, D. Fidock, 2017, Nature Communications.

Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity.

Amir Lerman, Joerg Herrmann, Nicola Ferri, 2013, Pharmacology & therapeutics.

Quinolone-3-Diarylethers: A New Class of Antimalarial Drug

Yuexin Li, David M. Shackleford, Susan A Charman, 2013, Science Translational Medicine.

Inhibition of Na+/Ca2+ exchange in membrane vesicle and papillary muscle preparations from guinea pig heart by analogs of amiloride.

G. Kaczorowski, E. Cragoe, P. Siegl, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Safety Pharmacology Assessment

B. Guth, P. Siegl, 2007, International Journal of Pharmaceutical Medicine.

Inhibition of Na + / Ca 2 " exchange in membrane vesicle and papillary muscle preparations from guinea pig heart by analogs of amiloride ( calcium influx / intracellular calcium stores / contractility )

E. Cragoe, P. Siegl, M. J. TRUMBLEt, 2022 .

Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors.

G. Kaczorowski, J. Reuben, M. L. García, 1986, The Journal of biological chemistry.

Quinolone-3-Diarylethers : A new class of drugs for a new era of malaria eradication

David M. Shackleford, R. Price, M. Mather, 2014 .

Anticoagulant Efficacy and Immunogenicity of the Selective Factor Xa Inhibitor Antistasin Following Subcutaneous Administration in the Rhesus Monkey

C. Dunwiddie, P. Siegl, G. Vlasuk, 1992, Thrombosis and Haemostasis.

α-Phenoxyphenylacetic acid derived angiotensin II antagonists with low nanomolar AT1/AT2 receptor subtype affinity (Part II)

W. Greenlee, R. Chang, V. J. Lotti, 1995 .

Synthesis of New Imidazo(1,2‐b)pyridazine Isosteres of Potent Imidazo( 4,5‐b)pyridine Angiotensin II Antagonists

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

J. Ehrhart, L. Peterson, P. Siegl, 2008, British journal of pharmacology.

Design and synthesis of P2-P1'-linked macrocyclic human renin inhibitors.

R J Lynch, T. Halgren, W. Greenlee, 1991, Journal of medicinal chemistry.

In vivo pharmacology of L-159,913, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.

W. Greenlee, P. Siegl, T. W. Schorn, 1995, Clinical and experimental hypertension.

Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension

P. Siegl, Salah D. Kivlighn, Theodore P. Broten, 1995, Journal of Hypertension - Supplement.

Cardiovascular responses to an isosterically modified prostaglandin analog in the anesthetized dog.

P K Siegl, P. Siegl, H C Wenger, 1985, European journal of pharmacology.

Positive inotropic responses in cardiac muscles: influence of stimulation frequency and species.

J. McNeill, P. Siegl, 1982, Canadian journal of physiology and pharmacology.

Failure of intravenous pentagastrin challenge to induce panic-like effects in rhesus monkeys

S. Iversen, P. Siegl, L. Schaffer, 1993, Neuropeptides.

Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction.

P. Siegl, S. Kivlighn, S. Kivlighn, 1994, Kidney international.

Inotropic responses, cyclic AMP, and time to peak tension in isolated cardiac preparations.

K. Macleod, P. Siegl, J. McNeill, 1982, Advances in myocardiology.

Comparison of the alpha-adrenergic agonists, phenylephrine and methoxamine in rabbit papillary muscles.

J. McNeill, P. Siegl, 1980, Research communications in chemical pathology and pharmacology.

Potent imidazole angiotensinII antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

Antagonism with dibenamine, D-600, and Ro 3-7894 to estimate dissociation constants and receptor reserves for cardiac adrenoceptors in isolated rabbit papillary muscles.

J. McNeill, P. Siegl, 1982, Canadian journal of physiology and pharmacology.

Calcium entry blocker activity of cyproheptadine in isolated cardiovascular preparations.

E. Baskin, P. Siegl, G. Morgan, 1984, The Journal of pharmacology and experimental therapeutics.

Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1 -receptor antagonist, MK-954.

T. Miyauchi, H. Ohta, P. Siegl, 2000, Journal of cardiovascular pharmacology.

In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for angiotensin AT2 receptors

W. Greenlee, R. Chang, R. Gibson, 1995 .

Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.

P. Siegl, R. Owen, M. Hubert, 1994, Laboratory investigation; a journal of technical methods and pathology.

Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis

E. Winzeler, S. Meister, J. Rayner, 2016, Nature.

Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics.

R J Lynch, M. Holloway, J. Doyle, 1991, Journal of medicinal chemistry.

Blockers of ATP sensitive potassium current are of potential benefit in ischaemic heart disease.

P. Siegl, 1994, Cardiovascular Research.

A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonists

W. Greenlee, R. Chang, Dooseop Kim, 1994 .

In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency.

R. Chang, R. Gibson, P. Siegl, 1995, The Journal of pharmacology and experimental therapeutics.

Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.

W. Greenlee, R. Chang, V. J. Lotti, 1994 .

Imidazo(4,5-b)pyridine-Based AT1/AT2 Angiotensin II Receptor Antagonists.

William J. Greenlee, W. Greenlee, R. Chang, 1994 .

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

A. Camm, R. Wallis, T. Hammond, 2003, Cardiovascular research.

Isolated lung strips of guinea pigs: responses to beta-adrenergic agonists and antagonists.

P. Siegl, R. Orzechowski, G. Rossi, 1979, European journal of pharmacology.

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies.

M Markert, J. Valentin, A. Bass, 2009, Journal of pharmacological and toxicological methods.